Saurin Chokshi
Hematology & Oncology · Memphis, TNNPI 1043576952
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $57,928 of the $85,896 with a category attached, or 67.4%. Exelixis Inc. accounts for 70.4% of it on its own, with 28 other manufacturers making up the rest. 2025 is the largest year on record at $46,335, 9.8 times the $4,715 reported in 2019.
Across 213 payments — averaging $403.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exelixis Inc.$60K
- Taiho Oncology, Inc.$17K
- Novartis$3K
- Beone Medicines USA, Inc.$2K
- F. Hoffmann-la Roche AG$2K
- AstraZeneca$332
- plus $2K from 23 others
Across 2 payments — averaging $10,828 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$22K
What the payments were for
- Consulting fees$9,79011%
- Speaking & faculty fees$57,92867%
- Travel & lodging$13,25415%
- Food & beverage$4,8916%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exelixis Inc. | 108 | $60,478 |
| Taiho Oncology, Inc. | 21 | $16,998 |
| Novartis | 11 | $2,548 |
| Beone Medicines USA, Inc. | 2 | $2,041 |
| F. Hoffmann-la Roche AG | 4 | $1,938 |
| AstraZeneca | 7 | $332 |
| Genentech USA, Inc. | 2 | $234 |
| E.r. Squibb & Sons, L.L.C. | 8 | $230 |
| Pfizer | 11 | $217 |
| Merck | 8 | $180 |
| Medtronic | 3 | $77 |
| Novocure Inc. | 1 | $73 |
| Amgen | 4 | $71 |
| Astellas Pharma US Inc | 3 | $68 |
| Janssen Scientific Affairs, LLC | 2 | $62 |
| Gilead | 2 | $49 |
| Bristol Myers Squibb | 2 | $37 |
| Johnson & Johnson(2 entities) | 2 | $35 |
| GSK | 1 | $28 |
| Lexicon Pharmaceuticals, Inc. | 2 | $25 |
| Incyte Corporation | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Beigene USA, Inc. | 1 | $21 |
| Integra Lifesciences Corporation | 1 | $21 |
| Array Biopharma Inc | 1 | $20 |
| Eisai Inc. | 1 | $20 |
| Puma Biotechnology, Inc. | 1 | $18 |
| Acrotech Biopharma Inc. | 1 | $16 |
| Tersera Therapeutics LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$85,896 in reported general payments places this provider in the 85th percentile of 251 hematology & oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TecentriqAtezolizumab | 15 | $162,454 |
| Sandostatin Lar DepotOctreotide Acetate,mi-Spheres | 12 | $53,762 |
| Ondansetron OdtOndansetron | 24 | $698 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 11 | $648 |
| Prochlorperazine Maleate | 24 | $516 |
| Oxycodone Hcl | 24 | $444 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisSandostatin Lar Depot | $2,548 | $53,76212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 251 hematology & oncology providers in Tennessee.
Other hematology & oncology in Memphis
- Ugochi OguMemphis$250K
- Patricia Adams-GravesMemphis$168K
- Donald GravenorMemphis$166K
- Aleksandar JankovMemphis$163K
- Brion RandolphMemphis$162K
- Kenneth AtagaMemphis$157K
- Raymond OsarogiagbonMemphis$117K
- Clyde JonesMemphis$54K
- Salil GoorhaMemphis$51K
- Muhammad RazaMemphis$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.